Informations générales (source: ClinicalTrials.gov)
DIStinguishing ChildrEn at Low Risk of Severe infectioN in Case of Febrile Neutropenia-7: Impact Study of a Clinical Decision Rule (DISCERN-FN7)
Interventional
N/A
University Hospital, Lille (Voir sur ClinicalTrials)
janvier 2021
décembre 2024
29 juin 2024
Febrile neutropenia (NF) is the leading cause of unscheduled hospitalization in children
with cancer. Management classically involves emergency admission to hospital for
intravenous antibiotic treatment until resolution of fever and neutropenia. However,
children with NF are a heterogeneous group with varying risks of severe infection
(10-29%). This approach, which is recognized as excessive for low-risk episodes of severe
infection, particularly in terms of quality of life and cost, is no longer recommended.
Management should move to a more personalized model that takes into account the
individual probability of severe infection. Clinical decision rules (CDRs) have been
proposed to facilitate risk stratification, but none are useful in our French population
because of insufficient reproducibility or effectiveness.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | 04/09/2024 13:49:39 | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Hop Jeanne de Flandre Chu Lille - 59037 - Lille - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- Followed for hemopathy or cancer,
- Presenting with post-chemotherapy NF,
- With social security coverage,
- With parents able to provide appropriate home supervision,
- Consent of parents and child if able to give consent.
- Followed for hemopathy or cancer,
- Presenting with post-chemotherapy NF,
- With social security coverage,
- With parents able to provide appropriate home supervision,
- Consent of parents and child if able to give consent.
- NF to diagnosis of tumor disease,
- Child with palliative care,
- Child who has had an allogeneic hematopoietic stem cell transplant within the past
year,
- NF immediately following an autologous hematopoietic stem cell transplant,
- Participation in the study during a previous NF,
- Curative antibiotic therapy or documented infection prior to admission,
- Initial management at a non-investigative center,
- Refusal of the child or parents to participate
Translated with www.DeepL.com/Translator (free version)